๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Genetic changes in the evolution of multidrug resistance for cultured human ovarian cancer cells

โœ Scribed by Timon P. H. Buys; Raj Chari; Eric H. L. Lee; May Zhang; Calum MacAulay; Stephen Lam; Wan L. Lam; Victor Ling


Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
819 KB
Volume
46
Category
Article
ISSN
1045-2257

No coin nor oath required. For personal study only.

โœฆ Synopsis


Abstract

The multidrug resistant (MDR) phenotype is often attributed to the activity of ATPโ€binding cassette (ABC) transporters such as Pโ€glycoprotein (ABCB1). Previous work has suggested that modulation of MDR may not necessarily be a single gene trait. To identify factors that contribute to the emergence of MDR, we undertook integrative genomics analysis of the ovarian carcinoma cell line SKOV3 and a series of MDR derivatives of this line (SKVCRs). As resistance increased, comparative analysis of gene expression showed conspicuous activation of a network of genes in addition to ABCB1. Functional annotation and pathway analysis revealed that many of these genes were associated with the extracellular matrix and had previously been implicated in tumor invasion and cell proliferation. Further investigation by whole genome tilingโ€path array CGH suggested that changes in gene dosage were key to the activation of several of these overexpressed genes. Remarkably, alignment of whole genome profiles for SKVCR lines revealed the emergence and decline of specific segmental DNA alterations. The most prominent alteration was a novel amplicon residing at 16p13 that encompassed the ABC transporter genes ABCC1 and ABCC6. Loss of this amplicon in highly resistant SKVCR lines coincided with the emergence of a different amplicon at 7q21.12, which harbors ABCB1. Integrative analysis suggests that multiple genes are activated during escalation of drug resistance, including a succession of ABC transporter genes and genes that may act synergistically with ABCB1. These results suggest that evolution of the MDR phenotype is a dynamic, multiโ€genic process in the genomes of cancer cells. ยฉ 2007 Wileyโ€Liss, Inc.


๐Ÿ“œ SIMILAR VOLUMES


Quantitative proteome analysis of multid
โœ Sang-Lin Li; Feng Ye; Wei-Jun Cai; Huai-Dong Hu; Peng Hu; Hong Ren; Fu-Fan Zhu; ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 271 KB

## Abstract In order to understand the molecular mechanisms of multidrug resistance (MDR) in ovarian cancer, we employed the proteomic approach of isobaric tags for relative and absolute quantification (iTRAQ), followed by LCโ€MS/MS, using the cisplatinโ€resistant COC1/DDP cell line and its parental

Doxorubicin induces expression of multid
โœ Chie Shinoda; Muneharu Maruyama; Takashi Fujishita; Junichi Dohkan; Hirofumi Oda ๐Ÿ“‚ Article ๐Ÿ“… 2005 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 646 KB

Multidrug resistance (MDR) is a major impediment to successful chemotherapy for lung cancer. Overexpression of multidrug resistance-associated protein 1 (MRP1) appears to be involved in MDR development in lung cancer cells. A number of chemotherapeutic agents including doxorubicin (DOX) were reporte

Recent advances in the discovery of flav
โœ Ahcรจne Boumendjel; Attilio Di Pietro; Charles Dumontet; Denis Barron ๐Ÿ“‚ Article ๐Ÿ“… 2002 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 189 KB

P-glycoprotein (P-gp) is a plasma membrane glycoprotein that confers multidrug resistance on cells by virtue of its ability to exclude cytotoxic drugs in an ATP-dependent manner. The most commonly considered hypothesis is that P-gp acts as an ATP-driven drug-export pump, the mechanism of which is no